The site of the Media Sphera Publishers contains materials intended solely for healthcare professionals.
By closing this message, you confirm that you are a certified medical professional or a student of a medical educational institution.

Login
EN
+7 (495) 482-4118
+7 (495) 482-0604
+8 800 250-18-12
  • (toll-free number for subscriptions)
    Mon-Fri from 10 a.m. to 6 p.m.

  • © 1998-2025
+7 (495) 482-43-29
EN
All journals
Journal
Year
Year
Search result: 0

Mangileva T.A.

Vernadsky Crimean Federal University

Kazantseva O.A.

Vernadsky Crimean Federal University;
Semashko Republican Clinical Hospital

Dranenko N.Y.

Vernadsky Crimean Federal University;
Semashko Republican Clinical Hospital

Sadovoi V.I.

Semashko Republican Clinical Hospital

Lischuk A.N.

Vishnevsky National Medical Research Center of High Medical Technologies

Inflammation and thrombosis in post-pericardiotomy syndrome

Authors:

Mangileva T.A., Kazantseva O.A., Dranenko N.Y., Sadovoi V.I., Lischuk A.N.

More about the authors

Journal: Russian Cardiology Bulletin. 2023;18(3): 23‑28

DOI: 10.17116/Cardiobulletin20231803123

Read: 1562 times

Download PDF (RU)
Contact the author
Table of contents

INFLAMMATION AND THROMBOSIS IN POST-PERICARDIOTOMY SYNDROME
INFLAMMATION AND THROMBOSIS IN POST-PERICARDIOTOMY SYNDROME

To cite this article:

Mangileva TA, Kazantseva OA, Dranenko NY, Sadovoi VI, Lischuk AN. Inflammation and thrombosis in post-pericardiotomy syndrome. Russian Cardiology Bulletin. 2023;18(3):23‑28. (In Russ.)
https://doi.org/10.17116/Cardiobulletin20231803123

 
ЭндоКард
Подписка 2026 Кардиологический вестник (Russian Cardiology Bulletin)
 
МСФ на ЯМ
Использование инфографики авторами научных работ
Close metadata
Recommended articles:
Effect of pro-inflammatory cyto­kines TNF-a and IL-1b on endo­thelial cells. Russian Cardiology Bulletin. 2024;(4-2):121-127
The role of systemic and local immu­nity in the pathogenesis of endo­metriosis of varying degrees of prevalence of the process: a modern view. Russian Journal of Human Reproduction. 2024;(5):6-14
High mobi­lity group protein B1 (HMGB1) and the pote­ntial for inflammation amplification in preeclampsia and threatened preterm labor. Russian Journal of Human Reproduction. 2024;(5):82-88
Perioperative prevention of bleeding in glaucoma surgery. Russian Annals of Ophthalmology. 2024;(5):118-124
The rela­tionship between inflammatory markers, fati­gue, and effort-based deci­sion-making in patients at clinical high risk for psychosis. S.S. Korsakov Journal of Neurology and Psychiatry. 2024;(10):85-91
Effi­cacy of alpha-glutamyl-tryptophan in the treatment of chro­nic atro­phic gastritis: case series. Russian Journal of Evidence-Based Gastroenterology. 2024;(4):121-128
Neuropeptide Y and inflammatory indi­ces in women after repeated cesa­rean section. Russian Bulletin of Obstetrician-Gynecologist. 2024;(6):35-40
Anti­fungal immu­nity in patients with chro­nic rhinosinusitis with nasal polyps. Russian Bulletin of Otorhinolaryngology. 2024;(6):40-45
Functional cyto­kine redu­ndancy in pregnancy. Russian Journal of Human Reproduction. 2024;(6):73-80
The level of hypo­xia-induced factor-1a and asso­ciated mole­cules in preeclampsia. Russian Bulletin of Obstetrician-Gynecologist. 2025;(1):5-10
Abstract:

Post-pericardiotomy syndrome (PPS) follows open cardiac surgery. This inflammatory process is accompanied by symptoms of pericarditis and/or pleuritis. Anti-inflammatory drugs are the main therapy in these patients. The theory of correlation between inflammation and clotting becomes widespread. Effectiveness of their complex treatment for infectious (new coronavirus infection) and non-infectious (coronary artery disease) diseases is being actively studied. Inflammation, previous surgery, cardiopulmonary bypass, and features of postoperative management can affect hemostasis system in patients with PPS. In addition, various medications for treatment of inflammation reduce or increase the risk of thrombosis. Combined administration of anti-inflammatory and antithrombotic therapy should increase the effectiveness of PPS treatment. Such therapy is really carried out, since the majority of cardiac surgical patients receive antiplatelet agents and/or anticoagulants in postoperative period to treat the underlying disease and prevent its complications. The problem of choosing the optimal combination of agents affecting inflammation and risk of thrombosis is very important.

Keywords:

post-pericardiotomy syndrome
inflammation
clotting

Authors:

Mangileva T.A.

Vernadsky Crimean Federal University

Kazantseva O.A.

Vernadsky Crimean Federal University;
Semashko Republican Clinical Hospital

Dranenko N.Y.

Vernadsky Crimean Federal University;
Semashko Republican Clinical Hospital

Sadovoi V.I.

Semashko Republican Clinical Hospital

Lischuk A.N.

Vishnevsky National Medical Research Center of High Medical Technologies

Received:

15.02.2023

Accepted:

14.03.2023

Close metadata

References:

  1. Adler Y, Charron P, Imazio M, Badano L, Barón-Esquivias G, Bogaert J, Brucato A, Gueret P, Klingel K, Lionis C, Maisch B, Mayosi B, Pavie A, Ristic A, Sabate Tenas M, Seferovic P, Swedberg K, Tomkowski W. ESC guidelines for the diagnosis and management of pericardial diseases 2015. Russian Journal of Cardiology. 2016;(5):117-162. (In Russ.). https://doi.org/10.15829/1560-4071-2016-5-117-162
  2. Association of Cardiovascular Surgeons of Russia (2020). Postcardiotomy syndrome. Clinical guidelines. Accessed April 21, 2020. (In Russ.). https://racvs.ru/upload/iblock/d06/d0614fbbd8418aaa1f5a6fe9a1c95bb4.pdf
  3. Lehto J, Gunn J, Karjalainen P, Juhani Airaksinen J, Kiviniemi T. Incidence and risk factors of postpericardiotomy syndrome requiring medical attention: the Finland postpericardiotomy syndrome study. Journal of Thoracic and Cardiovascular Surgery. 2015;149(5):1324-1329. https://doi.org/10.1016/j.jtcvs.2015.01.031
  4. Gabaldo K, Sutlic Z, Miskovic D, Knežević Praveček M, Prvulović D, Vujeva B, Cvitkušić Lukenda K, Hadžibegović I. Postpericardiotomy syndrome incidence, diagnostic and treatment strategies: experience AT two collaborative centers. Acta Clinica Croatica. 2019;58(1):57-62.  https://doi.org/10.20471/acc.2019.58.01.08
  5. Van Osch D, Nathoe HM, Jacob KA, Doevendans P, Diederik van Dijk, Suyker W, Dieleman J. Determinants of the postpericardiotomy syndrome: a systematic review. European Journal of Clinical Investigation. 2017;47(6):456-467.  https://doi.org/10.1111/eci.12764
  6. Buckley LF, Viscusi MM, Van Tassell BW, Abbate A. Interleukin-1 blockade for the treatment of pericarditis. European Heart Journal — Cardiovascular Pharmacotherapy. 2018;4(1):46-53.  https://doi.org/10.1093/ehjcvp/pvx018
  7. Dayer JM, Choy E. Therapeutic targets in rheumatoid arthritis: the interleukin-6 receptor. Rheumatology (Oxford). 2010;49(1):15-24.  https://doi.org/10.1093/rheumatology/kep329
  8. Heinrich PC, Behrmann I, Haan S, Hermanns H, Müller-Newen G, Schaper F. Principles of interleukin (IL)-6-type cytokine signalling and its regulation. Biochemical Journal. 2003;374(Pt 1):1-20.  https://doi.org/10.1042/BJ20030407
  9. Qazi BS, Tang K, Qazi A. Recent advances in underlying pathologies provide insight into interleukin-8 expression-mediated inflammation and angiogenesis. International Journal of Inflammation. 2011;2011:908468. https://doi.org/10.4061/2011/908468
  10. Zelova H, Hosek J. TNF-α signalling and inflammation: Interactions between old acquaintances. Inflammation Research. 2013;62(7):641-651.  https://doi.org/10.1007/s00011-013-0633-0
  11. Reikeras O, Borgen P. Activation of markers of inflammation, coagulation and fibrinolysis in musculoskeletal trauma. PLoS One. 2014;9(11):e107881. https://doi.org/10.1371/journal.pone.0107881
  12. Jaworska-Wilczynska M, Magalska A, Piwocka K, Szymański P, Kuśmierczyk M, Wąsik M, Hryniewiecki T. Low interleukin-8 level predicts the occurrence of the postpericardiotomy syndrome. PLoS One. 2014;9(10):e108822. https://doi.org/10.1371/journal.pone.0108822
  13. Stark K, Massberg S. Interplay between inflammation and thrombosis in cardiovascular pathology. Nature Reviews Cardiology. 2021;18(9):666-682.  https://doi.org/10.1038/s41569-021-00552-1
  14. Savage SA, Zarzaur BL, Gaski GE, McCarroll T, Zamora R, Namas RA, Vodovotz Y, Callcut RA, Billiar TR, McKinley TO. Insights into the association between coagulopathy and inflammation: abnormal clot mechanics are a warning of immunologic dysregulation following major injury. Annals of Translation Medicine. 2020;8(23):1576. https://doi.org/10.21037/atm-20-3651
  15. Grover SP, Mackman N. Tissue Factor An Essential Mediator of Hemostasis and Trigger of Thrombosis. Arteriosclerosis, Thrombosis, and Vascular Biology. 2018;38:709-725.  https://doi.org/10.1161/ATVBAHA.117.309846
  16. Foley JH, Conway EM. Cross Talk Pathways Between Coagulation and Inflammation. Circulation Research. 2016;118:1392-1408. https://doi.org/10.1161/CIRCRESAHA.116.306853
  17. Yamamoto M, Sato S, Hemmi H, Hoshino K, Kaisho T, Sanjo H, Takeuchi O, Sugiyama M, Okabe M, Takeda K, Akira S. Role of adaptor TRIF in the MyD88-independent toll-like receptor signaling pathway. Science. 2003;301:640-643.  https://doi.org/10.1126/science.1087262
  18. Schmidt CQ, Verschoor A. Complement and coagulation: so close, yet so far. Blood. 2017;130(24):2581-2582. https://doi.org/10.1182/blood-2017-10-811943
  19. Wu C, Lu W, Zhang Y, Zhang G, Shi X, Hisada Y, Grover SP, Zhang X, Li L, Xiang B, Shi J, Li XA, Daugherty A, Smyth SS, Kirchhofer D, Shiroishi T, Shao F, Mackman N, Wei Y, Li Z. Inflammasome activation triggers blood clotting and host death through pyroptosis. Immunity. 2019;50(6):1401-1411.e4.  https://doi.org/10.1016/j.immuni.2019.04.003
  20. Pleskova SN, Gorshkova EN, Borjakov AV, Krjukov RN. Morphological features of fast and classical netosis. Cytology. 2019;81(9):704-712. (In Russ.). https://doi.org/10.1134/S0041377119090098
  21. Dolgushin II, Mezentseva EA. Neutrophil extracellular traps in the fight against biofilm-forming microorganisms: hunters or prey? Journal of microbiology, epidemiology and immunobiology. 2020;97(5). (In Russ.). https://doi.org/10.36233/0372-9311-2020-97-5-9
  22. Warren OJ, Smith AJ, Alexiou C, Rogers PLB, Jawad N, Vincent C, Darzi AW, Athanasiou T. The inflammatory response to cardiopulmonary bypass: part 1—mechanisms of pathogenesis. Journal of Cardiothoracic and Vascular Anesthesia. 2009;23(2):223-231.  https://doi.org/10.1053/j.jvca.2008.08.007
  23. Bosch YP, Al Dieri R, ten Cate H, Nelemans PJ, Bloemen S, de Laat B, Hemker C, Weerwind PW, Maessen JG, Mochtar B. Measurement of thrombin generation intra-operatively and its association with bleeding tendency after cardiac surgery. Thrombosis Research. 2014;133(3):488-494.  https://doi.org/10.1016/j.thromres.2013.12.017
  24. Da Q, Teruya M, Guchhait P, Teruya J, Olson JS, Cruz MA. Free hemoglobin increases von Willebrand factor-mediated platelet adhesion in vitro: implications for circulatory devices. Blood. 2015;126(20):2338-2341. https://doi.org/10.1182/blood-2015-05-648030
  25. Boyle EM, Gillinov AM, Cohn WE, Ley SJ, Fischlein T, Perrault LP. Retained blood syndrome after cardiac surgery. Innovations (Phila). 2015;10(5):296-303.  https://doi.org/10.1097/IMI.0000000000000200
  26. Mangileva TA, Kazantseva OA, Karaseva IV. Peculiarity of clinical course of postpericardiotomy syndrome in different methods of surgery and postoperative antithrombotic therapy. Kardiologiia. 2021;61(4):53-59. (In Russ.). https://doi.org/10.18087/cardio.2021.4.n1374
  27. Lehto J, Kiviniemi T, Gunn J, Airaksinen J, Rautava P, Kytö V. Occurrence of Postpericardiotomy Syndrome: Association With Operation Type and Postoperative Mortality After Open-Heart Operations. Journal of the American Heart Association. 2018;7:e010269. https://doi.org/10.1161/JAHA.118.010269
  28. Imazio M, Lazaros G, Picardi E, Vasileiou P, Carraro M, Tousoulis D, Belli R, Gaita F. Intravenous human immunoglobulins for refractory recurrent pericarditis: a systematic review of all published cases. Journal of Cardiovascular Medicine. 2016;17(4):263-269.  https://doi.org/10.2459/JCM.0000000000000260
  29. Imazio M, Andreis A, De Ferrari GM, Cremer PC, Mardigyan V, Maestroni S, Luis SA, Lopalco G, Emmi G, Lotan D, Marcolongo R, Lazaros G, De Biasio M, Cantarini L, Dagna L, Cercek AC, Pivetta E, Varma B, Berkson L, Tombetti E, FIannone F, Prisco D, Caforio ALP, Vassilopoulos D, Tousoulis D, De Luca G, Giustetto C, Rinaldi M, Oh JK, Klein AL, Brucato A, Adler Y. Anakinra for corticosteroid-dependent and colchicine-resistant pericarditis: the IRAP (International Registry of Anakinra for Pericarditis) study. European Journal of Preventive Cardiology. 2020;27(9):956-964.  https://doi.org/10.1177/2047487319879534
  30. Gadi I, Fatima S, Elwakiel A, Nazir S, Al-Dabet MM, Rana R, Bock F, Manoharan J, Gupta D, Biemann R, Nieswandt B, Braun-Dullaeus R, Besler C, Scholz M, Geffers R, Griffin JH, Esmon CT, Kohli S, Isermann B, Shahzad K. Different DOACs control inflammation in cardiac ischemia-reperfusion differently. Circulation Research. 2021;128(4):513-529.  https://doi.org/10.1161/CIRCRESAHA.120.317219
  31. Kirchhof1 P, Ezekowitz MD, Purmah Y, Schiffer S, Meng IL, Camm AJ, Hohnloser SH, Schulz A, Wosnitza M, Cappato R. Effects of Rivaroxaban on Biomarkers of Coagulation and Inflammation: A Post Hoc Analysis of the X-VeRT Trial. TH Open. 2020;4(1):20-32.  https://doi.org/10.1055/s-0040-1701206
  32. Ichikawa H, Shimada M, Narita M, Narita I, Kimura Y, Tanaka M, Osanai T, Okumura K, Tomita H. Rivaroxaban, a direct factor Xa inhibitor, ameliorates hypertensive renal damage through inhibition of the inflammatory response mediated by protease-activated receptor pathway. Journal of the American Heart Association. 2019;8(8):e012195. https://doi.org/10.1161/JAHA.119.012195
  33. Martins GL, Duarte RCF, Vieira ÉLM, Rocha NP, Figueiredo EL, Silveira FR, Caiaffa JRS, Lanna RP, das Graças Carvalho M, Palotás A, Ferreira CN, Reis HJ. Comparison of Inflammatory Mediators in Patients With Atrial Fibrillation Using Warfarin or Rivaroxaban. Frontiers in Cardiovascular Medicine. 2020;7:114.  https://doi.org/10.3389/fcvm.2020.00114
  34. Harter K, Levine M, Henderson SO. Anticoagulation Drug Therapy: A Review. Western Journal of Emergency Medicine. 2015;16(1):11-17.  https://doi.org/10.5811/westjem.2014.12.22933
  35. Nishimura RA, Otto CM, Bonow RO, Carabello BA, Erwin 3rd JP, Fleisher LA, Jneid H, Mack MJ, McLeod CJ, O’Gara PT, Rigolin VH, Sundt 3rd TM, Thompson A. 2017 AHA/ACC focused update of the 2014 AHA/ACC guideline for the management of patients with valvular heart disease: a Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. Circulation. 2017;135(25):1159-1195. https://doi.org/10.1161/CIR.0000000000000503
  36. Solo K, Lavi S, Kabali K, Levine GN, Kulik A, John-Baptiste AA, Fremes SE, Martin J, Eikelboom JW, Ruel M, Huitema AA, Choudhury T, Bhatt DL, Tzemos N, Mamas MA, Bagur R. Antithrombotic treatment after coronary artery bypass graft surgery: systematic review and network meta-analysis. British Medical Journal. 2019;367:15476. https://doi.org/10.1136/bmj.l5476
  37. Nidorf SM, Fiolet ATL, Mosterd A, Eikelboom JW, Schut A, Opstal TSJ, The SHK, Xu XF, Ireland MA, Lenderink T, Latchem D, Hoogslag P, Jerzewski A, Nierop P, Whelan A, Hendriks R, Swart H, Schaap J, Kuijper AFM, van Hessen MWJ, Saklani P, Tan I, Thompson AG, Morton A, Judkins C, Bax WA, Dirksen M, Alings M, Hankey GJ, Budgeon CA, Tijssen JGP, Cornel JH, Thompson PL; LoDoCo2 Trial Investigators. Colchicine in patients with chronic coronary disease. New England Journal of Medicine. 2020;383(19):1838-1847. https://doi.org/10.1056/NEJMoa2021372
  38. Ridker PM, Everett BM, Thuren T, MacFadyen JG, Chang WH, Ballantyne C, Fonseca F, Nicolau J, Koenig W, Anker SD, Kastelein JJP, Cornel JH, Pais P, Pella D, Genest J, Cifkova R, Lorenzatti A, Forster T, Kobalava Z, Vida-Simiti L, Flather M, Shimokawa H, Ogawa H, Dellborg M, Rossi PRF, Troquay RPT, Libby P, Glynn RJ; CANTOS Trial Group. Antiinflammatory therapy with canakinumab for atherosclerotic disease. New England Journal of Medicine. 2017;377(12):1119-1131. https://doi.org/10.1056/NEJMoa1707914
  39. Alves Coelho MC, Santos CV, Neto LV, Gadelha MR. Adverse effects of glucocorticoids: coagulopathy. European Journal of Endocrinology. 2015;173(4):11-21.  https://doi.org/10.1530/EJE-15-0198
Contact the author
Email
Message
The publishing house "Media Sphere" does not provide treatment services, does not give recommendations on contacting medical institutions and specific specialists, on the prescription of medicines and dietary supplements.

Email Confirmation

An email was sent to test@gmail.com with a confirmation link. Follow the link from the letter to complete the registration on the site.

Email Confirmation

Contact us
If you have any questions, complaints or suggestions, please use this feedback form.
Email
Message
The publishing house "Media Sphere" does not provide treatment services, does not give recommendations on contacting medical institutions and specific specialists, on the prescription of medicines and dietary supplements.
Submit Application

You can become an author of one of our magazines, send a request and we will consider it in during the day.

Name
Phone
E-mail
Message
Login
Registration
E-mail
Password
Forgot Password?

Log in to the site using your account in one of the services

Password recovery
E-mail
Login
Register

We use cооkies to improve the performance of the site. By staying on our site, you agree to the terms of use of cооkies. To view our Privacy and Cookie Policy, please. click here.